Clarus, the pharmaceutical company that makes Jatenzo, a recently introduced oral formulation of testosterone, has been sued by Lipocine, the company that makes Tlando, a rival oral formulation candidate, for patent violations. Tlando has been denied approval for sale three times by the FDA, but Lipocine has applied again for approval. The trial is set to begin August 24, 2020.
The information is from this financial news article.
The information is from this financial news article.